Weill Medical College of Cornell University

• Home
• Cancer and Blood Disorders
  • Solid Tumor
    • Bladder Cancer
    • Breast Cancer
    • Colon Cancer
    • Esophageal Cancer
    • Gastric/Stomach Cancer
    • Head and Neck Cancer
    • Kidney/Renal Cancer
    • Liver Cancer
    • Lung Cancer
    • Melanoma
    • Ovarian/Peritoneal/Fallopian Tube Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Sarcoma
    • Soft Tissue Cancer

  • Multiple Myeloma
  • Leukemia and Myeloproliferative Disorders
    • Acute Lymphocytic Leukemia
    • Acute Myeloid Leukemia
    • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    • Chronic Myeloid Leukemia
    • Myelodysplastic Syndrome
    • Myelofibrosis
    • Polycythemia Vera

  • Lymphoma
    • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    • Hodgkin Lymphoma
    • Non-Hodgkin Lymphoma
    • Waldenstrom's Macroglobulinemia

  • Bone Marrow Transplant (BMT)
  • Benign Hematology
    • Anticoagulation
    • Bleeding and Platelet Disorders
• Cardiovascular/Heart
  • Aortic Aneurysms
  • Arrhythmias
  • Atrial Fibrillations
  • Coronary Artery Disease (CAD)
  • Inherited Heart Disease
  • Myocardial Infarction
  • Other Cardiovascular Diseases and Conditions
• Diabetes
• Gastrointestinal Diseases
  • Hepatitis
    • Hepatitis B
    • Hepatitis C
    • Hepatitis/HIV Co-Infection
  • Cancers of the Colon, Pancreas, Esophagus, Stomach
  • Celiac Disease
  • Crohn's Disease
  • Inflammatory Bowel Disease
  • Ulcerative Colitis
  • Other Gastrointestinal Diseases
• Geriatrics
  • Pain and Palliative Care
• Hepatitis
  • Hepatitis B
  • Hepatitis C
  • Hepatitis/HIV Co-infection
• Hypertension/High Blood Pressure
• HIV/AIDS and Infectious Diseases
• Kidney/Renal Disease
  • Kidney Transplants
• Lifestyle/Behavior Change
  • Medication Adherence
  • Hypertension Control
  • Colon Cancer Screening/Risk Reduction
• Pulmonary (Lung/Respiratory Tract) Disease
  • Asthma
  • Pneumonia
  • Pulmonary Fibrosis
  • Smokers
  • Other Respiratory/Lung Conditions
• Rheumatology Autoimmune Disease and Orthopedic Surgery
 
• Sleep Disorders
• Weight Loss/Obesity
• Healthy Volunteers

A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Study Status

Open to Enrollment

Study Description

This clinical trial is evaluating the effectiveness of an experimental drug called BMS-936558 in treating advanced or metastatic renal cell carcinoma (cancer that begins in the kidneys), compared to the approved drug Everolimus.

BMS-936558 is an antibody (a type of human protein) against PD-1, a protein involved in repressing the immune system. Blocking PD-1 with an antibody activates the immune system and enables it to fight tumors. BMS-936558 is administered via infusion.

Everolimus is an oral pill. It is FDA-approved to treat advanced kidney cancer.

Study participants will be randomly assigned to receive either:

• Arm A: BMS-936558 via infusion every 2 weeks
• Arm B: Everolimus pill taken by mouth daily

Participants may continue with study treatment as long as they are responding to therapy and not experiencing intolerable side effects. 

Disease Status and/or Stage

Advanced or Metastatic Kidney Cancer

Sponsor

Bristol-Myers Squibb

Key Eligibility

• Men and women age 18 and older
• Advanced or metastatic renal cell carcinoma
• Must have received one or two prior anti-angiogenic therapy regimens (including but but not limited to sunitinib, sorafenib, pazopanib, axitinib, tivozanib, and bevacizumab) for treating advanced or metastatic disease
• No more than 3 total prior systemic treatment regimens for advanced or metastatic disease, and must have progressed after the last treatment regimen and within 6 months of enrolling in the study
• Detailed eligibility reviewed when you contact the study team

Principal Investigator

Himisha Beltran, M.D.

Contact

• Renee Kahn, RN
• (212) 746-1851
• [email protected]

Protocol ID

BMS CA209-025-041